Using nanoparticles to enable simultaneous radiation and photodynamic therapies for cancer treatment.
This paper describes research into a new approach to cancer treatment through a combination of radiation and photodynamic therapies. The assumption is that supplementing conventional radiation therapy with photodynamic therapy (PDT) will enable the use of lower doses of radiation. Under this concept, scintillation or persistent luminescence nanoparticles with attached photosensitizers such as porphyrins are used as an in vivo agent for photodynamic therapy. The nanoparticle PDT agents are delivered to the treatment site. Upon exposure to ionizing radiation such as X-rays, the nanoparticles emit scintillation or persistent luminescence, which, in turn, activates the photosensitizers; as a consequence, singlet oxygen (1O2) is produced. Studies have shown that 1O2 can be effective in killing cancer cells. This is the conventional way in which PDT can augment the effectiveness of ionizing radiation. The innovation described in this study involves the use of in vivo luminescent nanoparticles so that an external light source is not required to support PDT. Consequently, application of the therapy can be more localized and the potential of damage to healthy cells is reduced. This new modality will provide an efficient, low-cost approach to PDT while still offering the benefits of augmented radiation therapy at lower doses.
Chen
Wei
W
Nomadics Inc, Stillwater, OK 74074, USA.
Zhang
Jun
J
D000818:Animals; D003131:Combined Modality Therapy; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry*; D006801:Humans; D049329:Nanostructures / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage* / Q000737:chemistry; D011878:Radiotherapy / Q000379:methods*
D004337:Drug Carriers; D017319:Photosensitizing Agents